Navigation Links
Avanir Pharmaceuticals to Participate in Two Conferences in March
Date:3/1/2012

ALISO VIEJO, Calif., March 1, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will participate in the following conferences in March.

  • Cowen & Company Healthcare Conference
    • Location: Boston Marriott, Boston , MA
    • Date: Tuesday March 6, 2012
    • Presentation time: 8:00 a.m. ET

  • 2012 Roth OC Growth Conference
    • Location: The Ritz Carlton, Laguna Niguel, CA
    • Date: Tuesday March 13, 2012
    • Presentation time: 4:30 p.m. PT

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a registered trademark owned by Avanir Pharmaceuticals, Inc.

© 2012 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System
2. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
3. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
4. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
5. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
6. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
7. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
8. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
9. Avanir Pharmaceuticals to Participate in Two Investor Conferences
10. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
11. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):